Are you looking for a versatile role in a high-growth company?
If you are seeking a position that offers more variety than the average role, you have just found it. As the Investor Relations Officer at Gubra, you will work at the intersection of capital markets and the company’s strategic development, with close interaction with executive management.
Listed on Nasdaq Copenhagen Main Market and employing around 300 people, Gubra combines cutting-edge research with a strong commitment to transparency and engagement with the capital markets.
What are we looking for?
We are looking for a structured, analytical, and proactive Investor Relations Officer to support and strengthen our dialogue with investors, analysts, and other capital market stakeholders.
This is an exciting opportunity to work at the intersection of science, strategy, and financial communication in a fast-growing biotech company, which generated revenue of DKK 2.6 billion in 2025.
Your role
As Investor Relations Officer, you will drive and execute Gubra’s investor relations strategy and ensure high-quality communication with the financial community. The position works closely with executive management.
Key responsibilities include:
- Leading the dialogue with investors and sell-side equity analysts
- Shaping and communicating the equity story and long-term strategic messaging
- Preparing external financial materials, including high-quality quarterly and annual reports, investor presentations, and related materials
- Conducting peer analysis, valuation benchmarking, and market intelligence
- Strengthening investor targeting and outreach to sell-side equity analysts
- Preparing earnings calls and investor meetings in close collaboration with executive management
- Drafting and coordinating company announcements and regulatory disclosures in compliance with market requirements
This role replaces the current Head of Investor Relations, who will transition into another role within Gubra.
Your profile
We are looking for a candidate with strong analytical capabilities, a commercial mindset, and the ability to operate in a high-performance environment. A scientific background or understanding, as well as a strong interest in the biotech/pharma industry, is considered an advantage.
Preferred qualifications:
- A university degree (preferably Master or PhD)
- At least 5 years of relevant experience, for example from:
- Capital markets (buy-side, equity research, or investment banking), or
- Strategic roles (management consulting or biotech/pharma industry)
- Ability to translate complex financial and scientific information into clear, compelling messaging
- Experience with financial modelling and analytical work
- Excellent PowerPoint and Excel skills
- Outstanding written and verbal communication skills in English
This central role requires drive, strong organizational skills, and the ability to effectively prioritize multiple tasks. You should thrive in a dynamic environment that retains an entrepreneurial mindset.
Location
Your workplace will be Gubra’s headquarters in Hørsholm, Denmark, where you will be part of the Finance team, reporting to the CFO.
Contact and Application
Please apply through our website using the “Apply” button. The deadline is April 12, 2026. Candidates will be invited for interviews on a rolling basis, and we reserve the right to close the posting before the expiration date. If you have questions, feel free to contact CFO Kristian Borbos at +45 3080 8035.
We look forward to receiving your application.
About Gubra
Gubra is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services striving for excellence at all levels. We insist on doing things efficiently – and often differently - to reach the results we aim for. Our vision is to become leaders in the path towards a more sustainable and healthier world. We do that by facilitating the discovery of new medicine, and by acting and inspiring others to fight the ongoing climate and biodiversity crises.
Gubra’s activities are focused on the early stages of drug development and are organised in two main highly synergistic business areas: Biotech and CRO Services. We generate our revenue by performing research for life science companies as well as by partnering projects from our discovery and development pipeline.
Our therapeutic focus is within metabolic and fibrotic diseases, and we specialize in in vivo pharmacology, ex vivo assays, drug profiling, histology, stereology and whole brain and organ imaging. In addition, we offer a full palette of advanced transcriptomics. Our ML/AI-driven peptide drug discovery platform streaMLine enables us to rapidly develop a peptide hit into a non-clinical candidate ready for development. Through a constant focus on high quality, scientific excellence, speed, and solid teamwork we have established ourselves as a highly professional and competent partner in the market.
People are our greatest asset, and our team consists of around 300 employees. The mix of people from different cultures and educational backgrounds combined with our entrepreneurial mindset have greatly impacted our working environment, which is characterized by entrepreneurial drive, scientific curiosity, and teamwork – we join forces!
